Nipent 2 mg/mL (Pentostatin INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 2 mg/mL

Nipent 2 mg/mL is a lyophilized powder for solution, used for intravenous administration. This medication, containing pentostatin, is often associated with certain types of cancer treatments. Learn more about its uses and effects.

Strength

2 mg/mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0409-0801-01) / 5 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Hospira, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Nipent 2 mg/mL is primarily used in the management of specific hematologic malignancies. It is often prescribed for conditions where targeted therapy is required. Patients and healthcare providers commonly seek information on what Nipent is used for, particularly in the context of cancer treatment protocols.

Side Effects

When administered as directed, Nipent 2 mg/mL may cause common effects such as nausea, fatigue, and injection site reactions. These effects can vary among individuals and are typically monitored by healthcare professionals. Always consult a medical provider for personalized advice.

Precautions & Warnings

Nipent 2 mg/mL should be handled with care, ensuring proper storage and preparation. It is essential to follow healthcare provider instructions for administration to minimize risks. Patients with certain medical conditions or allergies should discuss these with their healthcare provider before use.

Avoid Interactions

Nipent 2 mg/mL may interact with other medications, including those that affect the immune system or metabolism. It is important to inform healthcare providers about all current medications to avoid potential interactions. Always consult a healthcare professional for personalized advice.

Frequently Asked Questions

Nipent 2 mg/mL is used in the treatment of certain types of cancer, particularly hematologic malignancies.

Nipent 2 mg/mL is administered intravenously as a solution prepared from the lyophilized powder.

Common effects may include nausea, fatigue, and reactions at the injection site.

Potential interactions with other medications should be discussed with a healthcare provider.

Follow healthcare provider instructions for storage, preparation, and administration to ensure safety.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.